International Companies

Merck to buy drug targeting B-cell diseases for up to $1.3bn

By Michele Maatouk

Date: Friday 09 Aug 2024

(Sharecast News) - Merck said on Friday that it has agreed to buy biotech firm Curon's CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, for up to $1.3bn.
Under the terms of the deal, Merck will buy full global rights to CN201 for an upfront...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page